These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 29194765)

  • 41. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
    Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
    BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms.
    De Vos S; Demeyere K; De Cock H; Devriendt N; Schwarzkopf I; Fortrie R; Roggeman T; Meyer E; De Spiegelaere W; de Rooster H
    Res Vet Sci; 2022 Dec; 151():90-95. PubMed ID: 35872552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004).
    Camps-Palau MA; Leibman NF; Elmslie R; Lana SE; Plaza S; McKnight JA; Risbon R; Bergman PJ
    Vet Comp Oncol; 2007 Sep; 5(3):156-67. PubMed ID: 19754787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade.
    Mochizuki H; Thomas R; Moroff S; Breen M
    Chromosome Res; 2017 Jun; 25(2):129-143. PubMed ID: 28058543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of tumor enhancement by contrast-enhanced CT in solid tumor-bearing dogs treated with toceranib phosphate.
    Takagi S; Yamazaki H; Izumi Y; Hanazono K; Hoshino Y; Hosoya K
    Vet Radiol Ultrasound; 2020 Jul; 61(4):427-434. PubMed ID: 32162400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.
    London CA; Gardner HL; Rippy S; Post G; La Perle K; Crew L; Lopresti-Morrow L; Garton AJ; McMahon G; LaVallee TM; Gedrich R
    Clin Cancer Res; 2017 May; 23(10):2565-2574. PubMed ID: 27815356
    [No Abstract]   [Full Text] [Related]  

  • 48. Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features.
    Horta RS; Lavalle GE; Monteiro LN; Souza MCC; Cassali GD; Araújo RB
    Vet Pathol; 2018 Mar; 55(2):212-223. PubMed ID: 29338615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.
    Rippy SB; Gardner HL; Nguyen SM; Warry EE; Portela RA; Drost WT; Hostnik ET; Green EM; Chew DJ; Peng J; London CA
    BMC Vet Res; 2016 Nov; 12(1):257. PubMed ID: 27855679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
    Tjostheim SS; Stepien RL; Markovic LE; Stein TJ
    J Vet Intern Med; 2016 Jul; 30(4):951-7. PubMed ID: 27149912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia.
    Pérez ML; Culver S; Owen JL; Dunbar M; Kow K; Breen M; Milner RJ
    Anticancer Drugs; 2013 Nov; 24(10):1098-103. PubMed ID: 23995854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of Histological, Immunohistochemical, Clinical and Genetic Prognostic Factors Associated with the Response of Canine Mast Cell Tumours to Glucocorticotherapy.
    Dos Santos Horta R; Eunice Lavalle G; Narducci Monteiro L; Alves Dos Reis FBTM; de Pádua Costa M; Giuliano A; Dantas Cassali G; Dobson J
    J Comp Pathol; 2018 Nov; 165():72-81. PubMed ID: 30502801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigating Associations Between Proliferation Indices, C-kit, and Lymph Node Stage in Canine Mast Cell Tumors.
    Krick EL; Kiupel M; Durham AC; Thaiwong T; Brown DC; Sorenmo KU
    J Am Anim Hosp Assoc; 2017; 53(5):258-264. PubMed ID: 28792799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
    Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
    Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
    Remerowski SM; Herrera CL; Donnelly LL
    BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis.
    Meichner K; Kiupel M; Kasantikul T; Rakich P; Banovic F
    Vet Dermatol; 2019 Feb; 30(1):73-e22. PubMed ID: 30479052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
    Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
    BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).
    Lejeune A; Skorupski K; Frazier S; Vanhaezebrouck I; Rebhun RB; Reilly CM; Rodriguez CO
    Vet Comp Oncol; 2015 Sep; 13(3):267-80. PubMed ID: 23721492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
    Stanclift RM; Gilson SD
    J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.